The DPP7 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T-lymphocyte leukemia line, engineered for loss-of-function studies of the DPP7 gene. This pool of cells, carrying CRISPR/Cas9-mediated DPP7 gene disruption, provides a robust model for investigating the role of the ER-resident serine protease DPP7 in apoptosis signaling and T-cell biology. The polyclonal nature preserves heterogeneous editing events, enabling the study of DPP7 deficiency without clonal bias.
The parental Jurkat cell line is an immortalized human T-lymphocyte line originally established from the peripheral blood of a 14-year-old male with acute T-cell leukemia. Jurkat cells are widely employed to dissect T-cell receptor (TCR) signaling, activation mechanisms, and programmed cell death pathways. Their well-characterized signaling networks and ease of manipulation make them an ideal host for functional genomics studies of apoptosis-regulatory genes.
The DPP7 gene product is an ER-resident serine protease that mediates Fas-induced extrinsic apoptosis by removing N-terminal dipeptides. Upon Fas receptor ligation by FasL, DPP7 translocates to the cytoplasm, interacting with Bcl-2 family proteins to promote mitochondrial outer membrane permeabilization. This leads to cytochrome c release, APAF1 apoptosome assembly, and activation of caspase?9, caspase?3, and caspase?8. DPP7 integrates ER stress and apoptosis signals, with regulatory inputs from TNF-alpha, p53, NF???B, and TCR activation. DPP7 interacts with GRP78/BiP, FADD, and caspase?8, bridging death receptor signaling to intrinsic apoptosis via BID and BAX. Cleavage of caspase?3 and PARP ensues, while BCL?2 counteracts this pathway, with cell fate dictated by the balance of Bcl-2 family members.
In the Jurkat T-cell leukemia context, disruption of DPP7 markedly impairs Fas-mediated apoptosis, offering a powerful system to decode apoptosis dysregulation mechanisms relevant to lymphoid malignancies and autoimmune disorders. Because Jurkat cells rely on intact extrinsic and intrinsic apoptotic pathways for normal turnover and drug sensitivity, the DPP7 knockout model enables direct assessment of how loss of this ER?resident protease alters TCR?induced cell death, chemotherapy susceptibility, and ER stress responses. This model is especially pertinent for exploring therapeutic strategies that target apoptosis evasion in T?cell leukemia and lymphoma.
Researchers can employ this polyclonal knockout cell population in a variety of experimental setups. Apoptosis induction assays (Annexin V/PI staining) and caspase?3/7 activity measurements directly quantify cell death deficits. Western blotting for cleaved caspase?3, PARP, and cytochrome c release validate mitochondrial involvement, while co?immunoprecipitation reveals altered DPP7 protein complexes. Flow cytometric analysis of T?cell activation markers such as CD69 and CD25 interrogates crosstalk between TCR signaling and apoptosis. Chemotherapy sensitivity assays (e.g., MTT) and RT?qPCR profiling of apoptosis?related genes broaden the functional readouts. For further technical information and customized solutions, please contact Ascent Research.
